[{"data":1,"prerenderedAt":180},["ShallowReactive",2],{"drug-guanfacine-er":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":59,"contraindications":89,"warnings":99,"renal":100,"monitoring":101,"interactions":102,"review":103,"examples":106,"atc":112,"iran":114,"links":126,"populations":141,"usApproval":175},"guanfacine-er",1,{"fa":7,"en":8},"گوانفاسین آهسته‌رهش","Guanfacine extended-release","cardiovascular",{"fa":11,"en":12},"آگونیست α2A (غیرمحرک ADHD)","α2A agonist (non-stimulant ADHD)",[14],{"name":15,"market":16},"Intuniv","US",[18,19,20],"intuniv","اینتونیو","گوانفاسین",[22,35,43,51],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":30,"refs":31},"tab-1","tablet","oral","1 mg extended-release tablet",{"amount":5,"unit":28,"perUnit":24,"scored":29},"mg",false,[16],[32],{"source":33,"section":34},"fda-guanfacine-er","3",{"id":36,"form":24,"route":25,"label":37,"concentration":38,"markets":40,"refs":41},"tab-2","2 mg extended-release tablet",{"amount":39,"unit":28,"perUnit":24,"scored":29},2,[16],[42],{"source":33,"section":34},{"id":44,"form":24,"route":25,"label":45,"concentration":46,"markets":48,"refs":49},"tab-3","3 mg extended-release tablet",{"amount":47,"unit":28,"perUnit":24,"scored":29},3,[16],[50],{"source":33,"section":34},{"id":52,"form":24,"route":25,"label":53,"concentration":54,"markets":56,"refs":57},"tab-4","4 mg extended-release tablet",{"amount":55,"unit":28,"perUnit":24,"scored":29},4,[16],[58],{"source":33,"section":34},[60],{"id":61,"disease":61,"label":62,"population":65,"type":71,"unit":28,"dose":72,"refs":75,"notes":78},"adhd",{"fa":63,"en":64},"ADHD کودک و نوجوان ۶ تا ۱۷ سال — شروع ۱ mg روزانه، هدف ۰٫۰۵ تا ۰٫۱۲ mg\u002Fkg","ADHD age 6–17 — start 1 mg daily, target 0.05–0.12 mg\u002Fkg",{"minAge":66,"maxAge":69},{"value":67,"unit":68},6,"year",{"value":70,"unit":68},18,"titration",{"dividedDoses":5,"titration":73},{"start":5,"increment":5,"incrementEveryDays":74,"max":74},7,[76],{"source":33,"section":77},"2.2",[79],{"text":80,"refs":83},{"fa":81,"en":82},"افزایش حداکثر ۱ mg در هفته؛ هدف ۰٫۰۵ تا ۰٫۱۲ mg\u002Fkg\u002Fروز (۱ تا ۷ mg). قرص کامل بلعیده شود؛ با غذای پرچرب نه. ناگهانی قطع نشود. با گوانفاسین سریع‌رهش میلی‌گرم به میلی‌گرم جایگزین نشود.","Increase by no more than 1 mg\u002Fweek; target 0.05–0.12 mg\u002Fkg\u002Fday (1–7 mg). Swallow whole; not with high-fat meals. Do not stop abruptly. Not interchangeable mg-for-mg with immediate-release guanfacine.",[84,85,87],{"source":33,"section":77},{"source":33,"section":86},"2.1",{"source":33,"section":88},"2.3",[90],{"id":91,"severity":92,"text":93,"refs":96},"hyper","block",{"fa":94,"en":95},"حساسیت به گوانفاسین.","Hypersensitivity to guanfacine.",[97],{"source":33,"section":98},"4",[],[],[],[],{"status":104,"reviewer":105,"date":105},"unverified",null,[107],{"regimen":61,"formulation":23,"input":108,"expect":111},{"ageYears":109,"weightKg":110},10,30,{"perDose":5,"tabletsPerDoseRounded":5},[113],"C02AC02",{"status":115,"forms":116,"refs":121},"registered",[117],{"code":118,"en":119,"fa":120},"52018","GUANFACINE TABLET, EXTENDED RELEASE ORAL 4 mg","قرص آهسته‌رهش گوانفاسین ۴ میلی‌گرم",[122],{"source":123,"section":124,"url":125},"darooyab-generic","G-1699\u002FGuanfacine","https:\u002F\u002Fwww.darooyab.ir\u002FG-1699\u002FGuanfacine",[127,131,135,138],{"kind":128,"url":129,"label":130},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=201408","ANDA201408",{"kind":132,"url":133,"label":134},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=07a701e2-39b7-4bb1-a7c7-d9baed4ab18a","FDA Guanfacine ER",{"kind":136,"url":137,"label":113},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=C02AC02",{"kind":139,"url":125,"label":140},"darooyab","Guanfacine",{"pregnancy":142,"lactation":151,"pediatric":159,"geriatric":167},{"level":143,"text":144,"quote":147,"refs":148},"caution",{"fa":145,"en":146},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Available data with guanfacine over decades of use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.",[149],{"source":33,"section":150},"8.1",{"level":143,"text":152,"quote":155,"refs":156},{"fa":153,"en":154},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of guanfacine in human milk or the effects on the breastfed infant.",[157],{"source":33,"section":158},"8.2",{"level":143,"text":160,"quote":163,"refs":164},{"fa":161,"en":162},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Safety and efficacy of guanfacine extended-release tabletsin pediatric patients less than 6 years of age have not been established.",[165],{"source":33,"section":166},"8.4",{"level":143,"text":168,"quote":171,"refs":172},{"fa":169,"en":170},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","The safety and efficacy of guanfacine extended-release tablets in geriatric patients have not been established.",[173],{"source":33,"section":174},"8.5",{"kind":176,"refs":177,"id":130},"ANDA",[178],{"source":33,"section":179},"SPL approval \u002F marketing category",1792115182404]